Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.

IF 5
Zoë Ygj van Lierop, Alyssa A Toorop, Wouter Jc van Ballegoij, Tom Bg Olde Dubbelink, Eva Mm Strijbis, Brigit A de Jong, Bob W van Oosten, Bastiaan Moraal, Charlotte E Teunissen, Bernard Mj Uitdehaag, Joep Killestein, Zoé LE van Kempen
{"title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.","authors":"Zoë Ygj van Lierop,&nbsp;Alyssa A Toorop,&nbsp;Wouter Jc van Ballegoij,&nbsp;Tom Bg Olde Dubbelink,&nbsp;Eva Mm Strijbis,&nbsp;Brigit A de Jong,&nbsp;Bob W van Oosten,&nbsp;Bastiaan Moraal,&nbsp;Charlotte E Teunissen,&nbsp;Bernard Mj Uitdehaag,&nbsp;Joep Killestein,&nbsp;Zoé LE van Kempen","doi":"10.1177/13524585211028833","DOIUrl":null,"url":null,"abstract":"<p><p>In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1121-1125"},"PeriodicalIF":5.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/13524585211028833","citationCount":"30","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis (Houndmills, Basingstoke, England)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585211028833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 30

Abstract

In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.

Abstract Image

Abstract Image

Abstract Image

在COVID-19大流行期间,多发性硬化症患者的个性化b细胞定制剂量ocrelizumab
在这项观察性研究中,159名多发性硬化症患者在COVID-19大流行的激励下接受了个性化剂量的ocrelizumab。当CD19 b细胞计数大于或等于10个细胞/µL时安排重新给药(在前一次给药后24周开始,重复4周)。到重新给药或最后一次b细胞计数的中位间隔为34[30-38]周。无临床复发报告,少数患者表现出扩展残疾状态量表(EDSS)进展。月血清神经丝光水平在较长时间间隔内保持稳定。107例随访磁共振成像(MRI)扫描患者中2例(1.9%)显示放射学疾病活动。个体化给药ocrelizumab可显著延长间隔时间,短期疾病活动发生率低,鼓励未来对长期安全性和有效性的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信